



Article Effect of Inactivation Methods on SARS-CoV-2 Virion Protein and Structure

Emma K. Loveday ¹, Kyle S. Hain ², Irina Kochetkova ², Jodi F. Hedges ², Amanda Robison ², Deann T. Snyder ², Susan K. Brumfield ³, Mark J. Young ³, Mark A. Jutila ², Connie B. Chang ¹ and Matthew P. Taylor ²,*¹

- ¹ Department of Chemical & Biological Engineering, Montana State University, Bozeman, MT 59717, USA; emma.loveday@montana.edu (E.K.L.); connie.chang@montana.edu (C.B.C.)
- ² Department of Microbiology & Immunology, Montana State University, Bozeman, MT 59717, USA; kyle.hain@montana.edu (K.S.H.); ikochetk@montana.edu (I.K.); jodi.hedges@gmail.com (J.F.H.); amyrobisonmt@gmail.com (A.R.); deann.snyder@montana.edu (D.T.S.); mark.jutila@montana.edu (M.A.J.)
- ³ Department of Plant Science and Plant Pathology, Montana State University; Bozeman, MT 59717, USA; sbrumfield@montana.edu (S.K.B.); myoung@montana.edu (M.J.Y.)
- * Correspondence: mptaylor@montana.edu; Tel.: +1-406-994-7467

Abstract: The risk posed by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) dictates that live-virus research is conducted in a biosafety level 3 (BSL3) facility. Working with SARS-CoV-2 at lower biosafety levels can expedite research yet requires the virus to be fully inactivated. In this study, we validated and compared two protocols for inactivating SARS-CoV-2: heat treatment and ultraviolet irradiation. The two methods were optimized to render the virus completely incapable of infection while limiting the destructive effects of inactivation. We observed that 15 min of incubation at 65 °C completely inactivates high titer viral stocks. Complete inactivation was also achieved with minimal amounts of UV power (70,000 μ J/cm²), which is 100-fold less power than comparable studies. Once validated, the two methods were then compared for viral RNA quantification, virion purification, and antibody detection assays. We observed that UV irradiation resulted in a 2-log reduction of detectable genomes compared to heat inactivation. Protein yield following virion enrichment was equivalent for all inactivation conditions, but the quality of resulting viral proteins and virions were differentially impacted depending on inactivation method and time. Here, we outline the strengths and weaknesses of each method so that investigators might choose the one which best meets their research goals.

Keywords: SARS-CoV-2; UV inactivation; heat inactivation; ELISA; western blot; electron microscopy

1. Introduction

Novel SARS-CoV-2 has resulted in tremendous social and economic distress. Factors affecting the outcome of SARS-CoV-2 infection remain unclear, meriting considerable research investment. Research with infectious SARS-CoV-2 must be performed under biosafety level 3 (BSL3) conditions. While these conditions excel at keeping researchers and the community safe, they lack the expediency required for responding to a global pandemic. Researching SARS-CoV-2 at a more accessible, lower biosafety level requires that the virus first be rendered non-infectious [1]. Several effective methods have been devised to inactivate SARS-CoV-2, but unfortunately many of these techniques destroy the structural and genetic properties required for effective viral research.

In this study, we validated a pair of techniques that can each effectively neutralize SARS-CoV-2. The two techniques—heat inactivation and ultraviolet (UV) irradiation—both inactivate SARS-CoV-2 with differing effects on important viral characteristics [2–4]. We discovered that heat inactivation is ideal for retaining genetic material while UV irradiation allows for purification of high-quality virions. Here, we establish conditions for each method that results in complete inactivation of viral infectivity and detail the detection of viral components that will facilitate a researcher's particular experimental needs.



Citation: Loveday, E.K.; Hain, K.S.; Kochetkova, I.; Hedges, J.F.; Robison, A.; Snyder, D.T.; Brumfield, S.K.; Young, M.J.; Jutila, M.A.; Chang, C.B.; et al. Effect of Inactivation Methods on SARS-CoV-2 Virion Protein and Structure. *Viruses* **2021**, *13*, 562. https://doi.org/10.3390/v13040562

Academic Editor: Craig McCormick

Received: 9 March 2021 Accepted: 22 March 2021 Published: 26 March 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

2. Materials and Methods

2.1. Virus and Cells

SARS-CoV-2 strain WA01 was obtained from BEI Resources (Manassas, VA, USA). E6 Vero cells were obtained from ATCC (Manassas, VA, USA) and grown in DMEM (ThermoFisher, Waltham, MA, USA) supplemented with 10% FBS (Atlanta Biologicals, Minneapolis, MN, USA), and 1% pen-strep (ThermoFisher, Waltham, MA, USA). Viral stocks were propagated and titered on E6 Vero cells in DMEM supplemented with 2% FBS and 1% pen-strep. Viral stocks were made by collecting media from infected cell cultures showing extensive cytopathic effect and centrifuged 1000 RCF for 5 min to remove cellular debris. The clarified viral supernatant was then used for all subsequent inactivation studies. For determination of viral infectivity by plaque assay, E6 Vero cells were cultured then incubated with viral inoculum at limiting dilutions. Following inoculation, cells were over-layered with 1% methylcellulose (Sigma-Aldrich, St. Louis, MO, USA), DMEM supplemented with 2% FBS and 1% pen-strep and incubated for 3–4 days [1,5]. Cells were then fixed and stained with 0.5% methylene blue (Sigma-Aldrich, St. Louis, MO, USA) in 70% ethanol. Plaques were counted and the overall titer was calculated.

2.2. Heat Inactivation

SARS-CoV2 viral supernatants were aliquoted into 1.5 mL screw cap tubes and incubated in a 65 °C water bath for defined periods of time. Triplicate samples were generated for each time point tested. The water bath was set to 65 °C and validated with a thermometer. Tubes were placed into the water bath and held for 15, 20, 25, and 30 min. At each time interval three tubes were removed from the water bath and placed onto chilled Lab Armor Beads (ThermoFisher, Waltham, MA, USA) to quench the inactivation. Samples were then subjected to limiting dilution and assessed by plaque assay as described above.

2.3. UV Inactivation

To UV inactivate SARS-CoV-2 we employed a UV sterilizing oven (ThermoFisher, Waltham, MA, USA) placed within a biosafety cabinet. This sterilizer is equipped with 5 UV bulbs with peak emission around 254 nm (UV-C irradiation). UV exposure of viral supernatants was conducted in an open top 10 cm bacterial dish. Up to 15 mL of viral supernatant was placed into three separate dishes and put into the sterilizer where the lids were removed. The maximum depth of material was calculated at 1.5 mm. The dishes were irradiated for the indicated time and the power recorded. At each time point 250 μ L of viral supernatant was collected from the dish. Samples were then subjected to limiting dilution as indicated and assessed by plaque assay as described above.

2.4. RNA Quantification

The sequences of qPCR amplification primers for the SARS-CoV-2 RdRp (Orf1ab) gene were: D2-8F_nCoV_RdRP forward primer 5'-GTGARATGGTCATGTGTGGCGG-3', D2-8R_nCoV_RdRP reverse primer 5'-CARATGTTAAASACACTATTAGCATA-3' [6]. The sequence of RdRp gene TaqMan probe was: D2-8P2_nCoV_RdRP 5'-/FAM/CCAGGTGGWA CRTCATCMGGTGATGC/BHQ1/-3'. The sequences of qPCR amplification primers for the SARS-CoV-2 E gene were: Forward Primer: D2-7F_nCoV_E 5'-ACAGGTACGTTAA TAGTTAATAGCGT-3', Rev Primer: D2-7R_nCoV_E 5'-ATATTGCAGCAGTACGCACACA-3' [6]. The sequence of E gene TaqMan probe was: 5'-/FAM/ ACACTAGCCATCCT-TACTGCGCTTCG / BHQ1/-3'. Samples were amplified using SuperScript III Platinum One-Step qRT-PCR kit (Invitrogen, Carlsbad, CA, USA) with a final reaction volume of 10 µL. Primers and probes were ordered from Eurofins Genomics (Louisville, KY, USA) and were prepared as 100 μ M stocks. The working stocks of the primers were 25 μ M with a final reaction concentration of 800 nM. The working stock of the probe was 10 μ M with a final reaction concentration of 200 nM. Each reaction mix contained $0.05 \,\mu\text{M}$ 5-carboxy rhodamine-X (ROX) reference dye (Invitrogen, Carlsbad, CA, USA), $0.32 \text{ U}/\mu\text{L}$ SUPERase RNase Inhibitor (Invitrogen Carlsbad, CA, USA), and 1 µL of RNA. Thermocycling was

performed in a real-time qPCR machine (QuantStudio 3, Applied Biosystems, Foster City, CA, USA): 1 cycle for 30 min at 60 °C, 1 cycle for 2 min at 95 °C, and 40 cycles between 15 s at 95 °C and 1 min at 60 °C.

2.5. In Vitro Transcribed RNA

Standard curves were generated using serial dilutions of in vitro transcribed SARS-CoV-2 RdRp (Orf1ab) and E genes. To generate the in vitro transcribed RNA, gBlocks were ordered from IDT with a T7 promoter, forward and reverse primer sites, and probe sequence for the RdRp (Orf1ab) gene and E gene of SARS-Cov-2 Wuhan-Hu-1 strain. The gBlocks were in vitro transcribed using a MEGAscript T7 RNA Synthesis Kit (Ambion, Austin, TX, USA) following manufacturers instruction and purified over a GE Illustra Sephadex G-50 NICK column (Cytiva, Marlborough, MA, USA). RNA concentration was quantified using a NanoDrop spectrophotometer to determine the copy number per μL.

2.6. Sucrose Cushion Purification

Inactivated viral supernatant was overlayed onto a two-step sucrose density cushion as described previously to purify coronavirus particles [7]. The phosphate buffered sucrose at 17% and 30% were layered on the bottom of ultracentrifuge tubes. Viral supernatants were then layered on top of the sucrose and spun at 87,000 rcf for 2 h in a SW28 rotor equipped Beckman ultracentrifuge. The resulting supernatant was decanted, and each pellet was resuspended in up to 300 μ L of Phosphate Buffered Saline (PBS).

2.7. Gel Electrophoresis and Western Blotting

Protein content was analyzed using SDS-PAGE and Western blot. Briefly, resuspended virion pellets were mixed with 2× loading buffer, heated to 95 °C for 5 min then loaded onto a 10% SDS-PAGE gel. For direct detection of protein bands, gels were stained with Coomassie Brilliant Blue (Sigma-Aldrich, St. Louis, MO, USA). For detection of specific proteins, gel separated proteins were then transferred to PVDF membranes. Membranes were then blocked with 5% dried milk in PBS-0.1%Tween followed by incubation with SARS Coronavirus NP Monoclonal Antibody (E16C) (ThermoFisher Scientific, Catalog # MA1-7403) or SARS Coronavirus Spike polyclonal Serum (BEI Resources, Manassas, VA, USA). Primary antibody complexes were detected with goat anti-mouse (Invitrogen, Carlsbad, CA, USA) or goat anti-rabbit (Santa Cruz Biotech, Dallas, TX, USA) HRP conjugated secondary antibodies. Reactive bands were detected by ECL reagent and exposure to autoradiography film.

2.8. Electron Microscopy

Viral samples were negatively stained by placing 5 μ L of resuspended virion pellets on a 300 mesh formvar coated copper grid and left for 30 s. Excess liquid was then wicked off and 5 μ L of 2% uranyl acetate was applied. This stain was also wicked off after 30 s. The stained grids were viewed with a LEO 912 (Zeiss) transmission electron microscope operated at 100 KV accelerating voltage. Photos were taken with a 2 K \times 2 K Proscan camera (Proscan Electronic Systems, Lagerlechfeld, Germany).

2.9. Detection of Viral Antigens by ELISA

Suspensions of purified virions were coated onto 96-well ELISA plates at 4 μ g total protein per mL in PBS (50 μ L per well) and incubated at 4 degrees C overnight. Excess protein was decanted, and plates washed five times with 0.1% Tween-20 in PBS (wash buffer). Plates were blocked with 3% nonfat milk in wash buffer for 1 h. Mid-titer rabbit polyclonal serum obtained from BEI Resources (Manassas, VA, USA) was 2-fold serially diluted in 1% nonfat milk in wash buffer, applied to plates, and incubated for 2 h. Antisera was decanted and plates were washed as above, followed by incubation for 1 h at room temperature with a 1:3000 dilution of goat-anti-rabbit secondary antibody conjugated to HRP in wash buffer with 1% nonfat milk. The extent of antibody capture was measured by colorimetric

detection following treatment with TMB substrate (VWR Scientific, Radnor, PA, USA) and acid stop solution and quantified on a VERSAMax microplate reader (Molecular Devices, San Jose, CA, USA).

3. Results

3.1. Inactivation of SARS-CoV-2 by Exposure to Elevated Temperature

The first method of inactivation we employed was the well-established procedure of incubation at high temperature [2,8]. Viral supernatants were incubated in a water bath at 65 °C for specific intervals of time. The principle of this method is that excessive heat destabilizes viral proteins and assemblies, rendering them incapable of infection.

To test this inactivation method, a time course of heat exposure was conducted in screw-cap tubes containing 1.4 mL of SARS-CoV-2 viral stocks. The water bath was preheated for one hour with the temperature confirmed by an external digital thermometer. The tubes were placed into the water bath and held for 15, 20, 25, or 30 min. Previous data has demonstrated that heat inactivation of SARS-CoV-1 was variable at less than 15 min at 65 °C, so we proceeded with a minimum of 15 min exposure for SARS-CoV-2 [9]. At each time point three tubes were removed from the water bath and placed onto chilled beads to reduce temperature and prevent excessive inactivation. Samples were then subjected to limiting dilution and assessed by plaque assay, as detailed in Table 1. Our calculated titer at 0 min was 1.04×10^8 pfu/mL. Plaque assays performed on clarified viral supernatant heated at 65 °C for 15, 20, 25 and 30 min resulted in zero countable plaques (Table 1). This data demonstrates that a complete loss of viral infectivity was observed following heat inactivation for all time points tested after T0.

Time	Dilution Plated	Plaques Counted (Each Replicate)	Calculated Titer (pfu/mL)	
0 min	10^{-5}	215	$1.04 imes 10^8$	
	10^{-6}	14		
15 min	undiluted	0, 0, 0	0	
20 min	undiluted	0, 0, 0	0	
25 min	undiluted	0, 0, 0	0	
30 min	undiluted	0, 0, 0	0	

Table 1. Heat inactivation of 1.4 mL in 65 °C Water Bath.

3.2. Inactivation of SARS-CoV-2 by Exposure to UV-C Irradiation

To test the inactivation ability of UV-C, a time course of UV exposure was employed to determine the minimal amount of UV irradiation required to inactivate SARS-CoV-2 [4,9]. Up to 15 mL of clarified viral supernatant was placed in a lidless 10 cm Petri dish and exposed to UV-C irradiation as described in the Materials and Methods. UV-C treated virus was then subjected to limiting dilution and assessed by plaque assay. Initial testing looked at the inactivation of SARS-CoV-2 following 15 s, 30 s, 45 s, 1 min, 2 min, 3 min, and 4 min of UV-C exposure. The calculated titer of unexposed viral stocks was 4.5×10^7 pfu/mL. We observed no viral plaques at all UV-C exposure times. We therefore evaluated SARS-CoV-2 inactivation following 2 s, 5 s, 10 s, and 15 s of UV-C exposure.

The titer of unexposed stocks was 1.04×10^8 pfu/mL. Plaques were detected following 2 s and 5 s exposure, correlating to 1.39×10^5 pfu/mL and 10 pfu/mL, a 3- and 7-log reduction in infectivity, respectively. Exposures of 10 s or greater resulted in no detectable plaques demonstrating a complete loss of virus infectivity (Table 2, Figure 1).

Calculating Sufficient Levels of UV-C Irradiation

A common method of assessing efficacy of inactivation for UV-C irradiation is to calculate the susceptibility to irradiation to achieve a sufficient sterility assurance level (SAL) [10]. The SAL is a standard used to estimate the probability of a single viable pathogen being present in a sample following inactivation. This standard is often used by medical

device manufacturers employing various irradiation-based inactivation methods to validate that products are safe. For our purposes, calculating the SAL would not only help ensure inactivation of SARS-CoV-2, but also determine the minimum amount of UV-C necessary for sample inactivation. A common standard for terminal sterilization of medical devices is a SAL of 1×10^{-6} , which indicates that there is a 1 in 1,000,000 chance of finding a non-sterile unit. Achieving an SAL of 1×10^{-6} requires application of sufficient irradiation to reduce a known viable sample 6 log units past complete inactivation. To evaluate susceptibility of SARS-CoV-2 to UV irradiation required calculating the energy required to reduce titer by one log. We employed the following calculation to identify the dosing of UV irradiation that reduces infectivity of a sample by 90% or one log₁₀ (D10 value):

$$D10 \text{ value} = \frac{\text{UV Exposure Power}}{\log_{10}(\text{starting titer}) - \log_{10}(\text{ending titer})}$$
(1)

The reduction in titer following 2 and 5 s of UV-C exposure leads to the calculated dose needed to inactivate one log of SARS-CoV-2, which is 5320 μ J/cm² delivered by the UV sterilizer. Using this D10 value means that to reduce a 10⁸ pfu/mL stock solution to an SAL of 10⁻⁶, requires 14 D10 doses of UV-C irradiation, or 7.45 × 10⁴ μ J/cm². This is equivalent to 10.4 s of exposure in the UV sterilizer under the conditions we have described. It is critically important to utilize sufficient dosing of irradiation to provide a greater margin for potential error. We have chosen a minimum dose of 1.9 × 10⁵ μ J/cm² as sufficient to inactivate a stock of SARS-CoV-2 that is at 10⁸ pfu/mL or less.

Table 2. UV-C inactivation of 15 mL in open-top bacterial Dish.

Time	Cumulative UV Dose μJ/cm ²	Dilution Plated	Plaques Counted (Each Replicate)	Calculated Titer (pfu/mL)
0 s	0	10^{-5} 10^{-6}	215 14	$1.04 imes 10^8$
2 s	$1.82 imes 10^4$	10^{-2} 10^{-3}	TMTC ¹ , TMTC, 14 23, 57, 0	$1.39 imes 10^5$
5 s	$3.61 imes 10^4$	undiluted	6, 0, 0	10
10 s	$6.69 imes10^4$	undiluted	0, 0, 0	0
15 s	$9.78 imes10^4$	undiluted	0, 0, 0	0

¹ TMTC = Too many too count.



Figure 1. Plaque analysis and UV inactivation. (**A**) Infectious viral particles were detected by plaque assay under methylcellulose. Depicted is a single well of a six-well plate that had been inoculated with a limiting dilution of infectious viral stock. The inset is a higher magnification image of representative SARS-CoV-2 plaques. (**B**) A clarified solution containing infectious SARS-CoV-2 was subjected to UV exposure as detailed in Materials and Methods. Samples were taken from triplicate conditions at sequential exposures to UV-C irradiation. Each sample was then assessed for infectivity by the previously described plaque assay.

3.3. Detection of RNA from Inactivated Supernatants

Various methods are currently being used to inactivate SARS-CoV-2 samples prior to diagnostic testing by quantitative real-time PCR (qRT-PCR) or Loop Mediated Isothermal Amplification (LAMP) [11]. Given the importance of nucleic acids for these tests, we sought to determine if either of our methods would differentially impact RNA detection, and therefore potentially disrupt the ability to accurately assess the viral load in patient or environmental samples. We quantified the amount of RNA from both UV and heat inactivated samples and compared the number of genomes that could be detected to an untreated sample. RNA from the untreated, 1, 5, and 10 min UV-C exposed and 20, 25 and 30 min heat inactivated samples was extracted using the QiaAMP Viral RNA kit and quantified with two different primer sets targeting the RdRp (Orf1ab) or E gene of SARS-CoV-2. In vitro transcribed RdRp or E gene RNA was used to generate standard curves for genome copy quantification. A serial dilution of each in vitro transcribed RNA was performed to ensure that our different samples fell within the linear detection limit of our assay. The dilutions of each in vitro transcribed RNA ranged from 10^8 to 10^3 copies per μ L and was plotted against the Ct value to determine the efficiency of each reaction. The RdRp gene primer pairs produced a reaction efficiency around 95.22% and all samples fell within the linear range of the assay (Figure 2A). For the E gene primer pairs the reaction efficiency was determined to be 98.71% and again, all samples fell within the linear range of the assay (Figure 2B).



Figure 2. Detection of RNA genomes following inactivation. Inactivated viral supernatants were subjected to RNA extraction and detection. (**A**,**B**) A standard curve was produced for the RdRp (**A**) and E (**B**) assays using serial diluted in vitro transcribed RNA (brown circles). RNA from UV and heat inactivated samples (light blue and dark blue, respectively) fall within the linear detection of both assays. The untreated genomic RNA is represented by the pink circle. (**C**) Quantification of the untreated RNA, UV inactivated samples at 1, 5 and 10 min and heat inactivated samples at 20, 25 and 30 min are shown. The mean and SEM from triplicate wells for the RdRp (tan) and E (grey) assays are shown. Samples inactivated via UV-C exposure for 1, 5, or 10 min were exposed to 4×10^5 , 2×10^6 , and $4 \times 10^6 \mu J/cm^2$, respectively. (**D**) Quantification of untreated RNA and UV inactivated samples at 2, 5, 10, 30 and 60 s for the RdRp (tan) and E (grey) assays.

For the untreated sample, an average of 2.3×10^8 genome copies per μ L were detected by the RdRp primers and 1.4×10^8 genome copies per μ L were detected by the E primers (Figure 2C). In contrast, UV inactivated samples treated for 1 min had a 2 and 3 log reduction in the amount of RNA detected with an average of 1.8×10^6 and 1.9×10^5 genome copies per μ L detected by the RdRp and E assays, respectively (Figure 2C). The amount of RNA detected was further reduced as UV exposure times increased to 5 and 10 min (Figure 2C). UV-C exposure for 10 min resulted in detection of an average of 1.2×10^5 and only 3.9×10^3 genome copies with the RdRp and E primers, respectively (Figure 2C). The genomic location of the RdRp and E genes, along with the increased variability in detection via qRT-PCR, suggests that degradation of the RNA may be proceeding from the 3' end of the genome following exposure to UV-C radiation. In contrast, heat inactivation at T20 and T25 resulted in an average of 1.2×10^8 genome copies per μ L and at T30 an average of 1.6×10^8 genome copies per μ L with the RdRp primers (Figure 2C). The E primers detected an average of 2.6×10^7 , 3.6×10^7 , and 2.7×10^7 genome copies per μ L from viral stocks heat inactivated for 20, 25, and 30 min, respectively (Figure 2C). Compared to UV treatment, heat inactivation did not disrupt the SARS-CoV-2 genome allowing for comparable amounts of RNA detected compared to untreated controls. Further investigation into the impact of UV-C exposure for less than 1 min demonstrates that RNA degradation, resulting in reduced detection, proceeds in a linear fashion with an average of 7.2×10^8 and 9.5×10^7 genomes detected at 0 s of UV-C exposure for RdRp and E, respectively (Figure 2D). The quantification of RdRp and E RNA is reduced to 1×10^8 and 2.3×10^7 copies, respectively, following 10 s of UV-C exposure. A full minute of UV-C exposure results in a loss of almost 2 logs for the RdRp (1.1×10^7) and E (1.8×10^6) assay. The analysis of timepoints between 0 and 60 s (Figure 2D) resulted in less loss of RNA detection than our previous analysis at 1, 5 and 10 min of UV-C exposure (Figure 2C). However, the trend remained and indicates a significant reduction of detectable RNA following UV-C exposure that should be considered when using irradiated or UV inactivated samples for qRT-PCR analysis. In addition, the E primers resulted in slightly lower amount of RNA detected, which could be the result of degradation from the 3' end of the genome and should be considered when designing qRT-PCR assays for use with heat inactivated samples.

3.4. Purification of Virions from Inactivated Supernatant

To remove contaminates from inactivated virions, we employed a two-step sucrose gradient purification previously described for the porcine epidemic diarrhea virus (PEDV) [7]. Inactivated viral supernatants were subjected to high-speed centrifugation through a twostep sucrose gradient to purify and concentrate virions for downstream applications. Pelleted material was resuspended in PBS resulting in highly concentrated SARS-CoV-2 virions.

Following resuspension, we assessed the purity of viral proteins by SDS-PAGE prior to visualization by Coomassie or Western blot for viral proteins (Figure 3). Fewer Coomassie stained bands were observed from UV-C inactivated material than from heat inactivated material. This could indicate that UV-C treated virions are damaged or cross-linked together, reducing detection of SARS-CoV-2 virion proteins. More likely, the heat inactivation results in extensive protein denaturation and aggregation. These aggregated proteins may non-specifically bind to virions, or co-precipitate in our purification scheme.

The differences in protein yield are also reflected in Western blot analysis of specific viral proteins. We see the most intense bands of both Spike and Nucleocapsid protein come from heat inactivated material with no obvious differences between 20 and 30 min of heat exposure. UV-C irradiation results in reduced quantities of both the aforementioned viral proteins. More importantly, excessive UV-C exposure at 5- and 10-min results in a clear increase in a slower migrating species of Spike protein. This slowly migrating species is likely the result of cross-linking between the proteolytically cleaved portions of the Spike. Additionally, we observed that greater UV exposure produced a minor, but detectable, amount of slower migrating N-protein that was not detected at 1 min of UV exposure.



Figure 3. Comparison of virion protein quality following inactivation. Viral supernatants inactivated by UV or Heat exposure were loaded onto a two-step sucrose gradient and subjected to ultracentrifugation. The resulting pellets were resuspended in PBS and analyzed for protein content. (**A**) 5 μ g of resuspended pellets from the two inactivation conditions were loaded onto a 10% SDS-PAGE gel that was then subjected to Coomassie staining. (**B**) 0.2 μ g of each pellet was run on a 10% gel and transferred to PVDF membrane for Western analysis for SARS-CoV-2 Spike or Nucleocapsid. Protein extracted from SARS-CoV-2 infected cells was run as a positive control.

3.5. Electron Microscopy Analysis of Inactivated Virions

To better understand the state of the virion following inactivation and purification, we subjected the resuspended, semi-purified virion pellets to examination under an electron microscope (Figure 4). In all conditions, spherical structures with protuberances that match descriptions of SARS-CoV-2 virions were readily detectable [12]. UV inactivated virions revealed the most intact viral particles, with the virions subjected to the lowest UV exposure appearing the most "normal". Heat inactivated material, while mostly comparable in appearance, exhibited deformed and disrupted virion structures that increased in prevalence at longer inactivation times.



Figure 4. Electron microscopy analysis of virion morphology. Semi-purified virion preparations were spotted onto a grid and imaged to assess virion morphology. The top row of images was taken from UV inactivated samples. The bottom row of images was taken from heat inactivated samples. Relative size is indicated by the scale bar in the lower corner of each image.

3.6. Detection of Inactivated and Purified Virions by ELISA

The quality of inactivated virus material is an important consideration when developing diagnostic assays or vaccines. To this end, we assessed the relative detection of our inactivated viruses using an indirect ELISA. Wells were coated with equivalent amounts of viral protein prior to being exposed to a dilution series of SARS-CoV-2-specific poly-clonal rabbit serum. Negative control rabbit serum was used to measure the background binding capacity of the different preparations. As depicted in Figure 5, all purified virion preparations had marginal background signal from the negative control serum. We observed that the resulting colorimetric response was influenced by the type and extent of inactivation. Optimal detected from the 10-min sample. Heat inactivated material was also detected, but at a lower rate than that of UV-C inactivated samples. Reduced detection in the ELISA can be caused either by reduced antigen detection or by reduced protein coating of the dishes. Together, our observations suggest that short duration UV exposure produces the higher quality of material for detection by ELISA compared to heat inactivation.



Figure 5. Indirect ELISA detection of virions. Semi-purified virions from both UV and Heat inactivated methods were used as coating antigen in an indirect ELISA assay. Poly-clonal serum from negative control or SARS-CoV-2 Spike immunized rabbits was used as the primary antibody with anti-rabbit-HRP and colorimetric detection was used to measure the extent of antibody capture. Plotted is the resulting O.D. measurements from a representative set of dilutions.

4. Discussion

Viral inactivation is a powerful tool for mitigating research risk while expediting scientific objectives. The most useful methods of inactivation are effective and reliable without being overly destructive to virion components. The goal of this study was to validate two methods of SARS-CoV-2 inactivation—heat inactivation and UV-C irradiation—and assess their respective effects on virion components. We observed that both techniques were wholly effective at inactivating virus with minimal effects on virion morphology and antibody mediated detection.

An important initial aspect of this study was to determine the appropriate levels of viral inactivation by both methods so samples could be safely removed from our BSL3 facility for downstream analysis or use in other experimental protocols. Insufficient inactivation puts researchers at risk for exposure, while excessive inactivation can compromise important virion components and limit research applicability. In this study, we observed that excessive UV-C irradiation reduced SARS-CoV-2 detection by ELISA, likely due to significant cross-linking of viral proteins observed by Western Blot. Many studies published on the inactivation of beta-coronaviruses use significantly higher levels of UV-C irradiation than what we report here [4,9,13]. Our methods significantly reduced UV-C

exposure by optimizing experimental conditions. Working in a biosafety cabinet, we removed the plastic lids from the 10 cm dishes that would have otherwise absorbed much of the incoming UV-C radiation. As UV-C is attenuated as a function of depth, we also enhanced the surface area of exposure while limiting the fluid depth to less than 2 mm, ensuring equal inactivation of the sample throughout and limiting overexposure. In a similar vein, heat inactivation was performed in small volume tubes (1.5 mL) in a water bath to ensure the even heating and inactivation of samples throughout.

It is clear that while both methods effectively inactivated SARS-CoV-2, each had unique effects on the virus that in turn affected downstream applications. Heat treatment is a common method of viral inactivation that works via the denaturation of viral proteins and disassembly of virion structures. It was interesting to see that heat inactivation, even at excessive times, left virions mostly intact, although deformations and reduced antigenicity were observed. This was an encouraging observation for protocols that enrich virions based on the biophysical properties of intact structures. We also observed that while heat treatment eliminated infectivity, viral genomes were left largely intact. This made heat inactivation the preferred method for evaluations using genome-based assays like PCR or Loop-Mediated isothermal amplification (LAMP). Unlike heat inactivation, UV-C irradiation works primarily by damaging SARS-CoV-2 RNA, preventing the transcription and replication of viral genomes. We observed this method to be especially effective at retaining virion morphology and antigenicity. Visualization of inactivated virions by electron microscopy showed that UV-C irradiated samples retained much of their native viral structure. These samples were also significantly more detectable by ELISA compared to samples that were heat inactivated, though it remains unknown if this is due to antigen preservation or through on protein binding to the polystyrene plate prior to antibody capture. Both UV-C irradiated, and heat inactivated samples yielded near equivalent amounts of protein, though quality of viral proteins varied when assessed by Western blot. This is important to note if considering downstream applications for antigen detection or vaccine development.

A number of quality studies have evaluated effective inactivation through various means. Chemical inactivation can be achieved with detergents, fixatives, or other crosslinking reagents. Studies like Jureka et al. demonstrated excellent inactivation with Trizol, formalin and beta-propiolactone (BPL). Treatment with BPL is purportedly effective, with limited influence on SARS-CoV-2 virion morphology and viral proteins [1,14]. Similarly, heat and BPL have been extensively used for treatment of both patient samples and viral preparations to reduce biosafety risk and assist in the development of diagnostic assays [14,15]. Jureka et al. demonstrate that 56 °C inactivation requires more than 30 min exposure, while 100 °C incubation is effective within 5 min. Our findings at 65 °C are in line with prior published reports for SARS-CoV-1 and 2 [2,9,14]. Despite differences in susceptibility or extent, we have identified and compared conditions of UV and heat inactivation that effectively inactivated SARS-CoV-2. Like many published studies, our procedures strike a balance between effective inactivation and preservation of viral structures for downstream diagnostic processes.

5. Conclusions

The results of our study indicate that both heat inactivation and UV-C irradiation are viable methods for inactivating SARS-CoV-2 for use in BSL-2 laboratory environments. Both methods left the virion mostly intact while effects on other viral properties differed. From this study it is clear that both the extent and method of inactivation have important ramifications on SARS-CoV-2 virions that should be considered when planning experiments or downstream applications.

Author Contributions: Conceptualization, M.P.T., E.K.L. and M.A.J.; methodology, M.P.T., E.K.L., K.S.H., I.K., J.F.H., A.R., D.T.S. and S.K.B.; resources, M.P.T., C.B.C., M.J.Y. and M.A.J.; writing—original draft preparation, M.P.T., E.K.L. and K.S.H.; writing—review and editing, M.P.T., E.K.L., K.S.H., I.K., J.F.H., A.R., D.T.S. and S.K.B.; supervision, M.P.T., C.B.C., M.J.Y. and M.A.J. All authors have read and agreed to the published version of the manuscript.

Funding: Funding for this research was provided by the Montana State University Vice President of Research and Economic Development COVID Research Fund.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Acknowledgments: The following reagents were obtained through BEI Resources, NIAID, NIH: 2019 Novel Coronavirus, strain 2019-nCoV/USA-WA1/2020, NR-52281 and Rabbit Sera Control Panels, Polyclonal Anti-SARS-CoV Spike Protein, NR-4569. Sequences for primer development were kindly provided by Jon Shultz at NIH Rocky Mountain Labs, Hamilton, MT. This work would not have been possible without the support of MSU's Office of Research Compliance and the JRL management team of Kirk Lubick, Ryan Bartlett and Kathryn Jutila.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Jureka, A.S.; Silvas, J.A.; Basler, C.F. Propagation, Inactivation, and Safety Testing of SARS-CoV-2. *Viruses* 2020, 12, 622. [CrossRef]
 [PubMed]
- 2. Pastorino, B.; Touret, F.; Gilles, M.; de Lamballerie, X.; Charrel, R.N. Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics? *Viruses* **2020**, *12*, 735. [CrossRef] [PubMed]
- 3. Abraham, J.P.; Plourde, B.D.; Cheng, L. Using heat to kill SARS-CoV-2. Rev. Med. Virol. 2020, 177, 71. [CrossRef] [PubMed]
- 4. Heilingloh, C.S.; Aufderhorst, U.W.; Schipper, L.; Dittmer, U.; Witzke, O.; Yang, D.; Zheng, X.; Sutter, K.; Trilling, M.; Alt, M.; et al. Susceptibility of SARS-CoV-2 to UV Irradiation. *Am. J. Infect. Control* **2020**, *48*, 1273–1275. [CrossRef] [PubMed]
- Hotchin, J.E. Use of Methyl Cellulose Gel as a Substitute for Agar in Tissue-Culture Overlays. *Nature* 1955, 175, 352. [CrossRef] [PubMed]
- Corman, V.M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D.K.; Bleicker, T.; Brünink, S.; Schneider, J.; Schmidt, M.L.; et al. Detection of Novel Coronavirus (2019-nCoV) by Real-Time RT-PCR. *Eurosurveillance* 2020, 25, 2000045.
- 7. Hofmann, M.; Wyler, R. Enzyme-linked immunosorbent assay for the detection of porcine epidemic diarrhea coronavirus antibodies in swine sera. *Vet. Microbiol.* **1990**, *21*, 263–273. [CrossRef]
- Wu, Z.-G.; Zheng, H.-Y.; Gu, J.; Li, F.; Lv, R.-L.; Deng, Y.-Y.; Xu, W.-Z.; Tong, Y.-Q. Effects of Different Temperature and Time Durations of Virus Inactivation on Results of Real-time Fluorescence PCR Testing of COVID-19 Viruses. *Curr. Med. Sci.* 2020, 9, 19. [CrossRef] [PubMed]
- 9. Darnell, M.E.R.; Subbarao, K.; Feinstone, S.M.; Taylor, D.R. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J. Virol. Methods 2004, 121, 85–91. [CrossRef] [PubMed]
- 10. von Woedtke, A.K.T. The limits of sterility assurance. GMS Krankenh. Interdiszip. 2008, 3, 789–793.
- 11. Wang, Y.; Song, W.; Zhao, Z.; Chen, P.; Liu, J.; Li, C. The impacts of viral inactivating methods on quantitative RT-PCR for COVID-19. *Virus Res.* **2020**, *285*, 197988. [CrossRef] [PubMed]
- 12. Neuman, B.W.; Adair, B.D.; Yoshioka, C.; Quispe, J.D.; Orca, G.; Kuhn, P.; Milligan, R.A.; Yeager, M.; Buchmeier, M.J. Supramolecular Architecture of Severe Acute Respiratory Syndrome Coronavirus Revealed by Electron Cryomicroscopy. *J. Virol.* **2006**, *80*, 7918–7928. [CrossRef] [PubMed]
- 13. Tsunetsugu-Yokota, Y. Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen. In *SARS and Other Coronaviruses*; Laboratory Protocols; Humana Press: Totowa, NJ, USA, 2008; Volume 454, pp. 119–126.
- Cerutti, H.; Ricci, V.; Tesi, G.; Soldatini, C.; Castria, M.; Vaccaro, M.N.; Tornesi, S.; Toppi, S.; Verdiani, S.; Brogi, A. Large scale production and characterization of SARS-CoV-2 whole antigen for serological test development. *J. Clin. Lab. Anal.* 2021, e23735. [CrossRef]
- 15. Burton, J.; Love, H.; Richards, K.; Burton, C.; Summers, S.; Pitman, J.; Easterbrook, L.; Davies, K.; Spencer, P.; Killip, M.; et al. The effect of heat-treatment on SARS-CoV-2 viability and detection. *J. Virol. Methods* **2021**, 290, 114087. [CrossRef]